
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
β-Arrestin-2 CRISPR Activation Plasmid (h) | sc-416686-ACT | 20 µg | $397.00 | |||
β-Arrestin-2 CRISPR Activation Plasmid (h2) | sc-416686-ACT-2 | 20 µg | $397.00 |
ARRB2 encodes β-Arrestin-2, a multifunctional adaptor that regulates G protein–coupled receptor (GPCR) desensitization, internalization, and trafficking following receptor phosphorylation by GRKs. Beyond terminating G protein signaling, β-Arrestin-2 scaffolds signaling complexes that modulate MAPK/ERK, PI3K–AKT, and NF-κB pathways, shaping signal duration and subcellular localization. Through these interactions, ARRB2 influences cell migration, inflammatory signaling, and receptor-biased signaling across diverse GPCR systems. Dysregulated β-arrestin–dependent signaling has been linked in the literature to cancer-associated signaling networks, cardiometabolic regulation, and neuroimmune processes, supporting its use as a mechanistic node in pathway-focused studies.
β-Arrestin-2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ARRB2 expression without altering the underlying DNA sequence.
β-Arrestin-2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ARRB2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ARRB2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous β-Arrestin-2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ARRB2 locus and enabling the study of β-Arrestin-2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of β-Arrestin-2 pathway restoration in tumor cells with silenced or reduced ARRB2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.